Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 1

2(25.0%)

8Total

Phase 2(6)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00290381Phase 1Completed

The Effects of OC000459 on Nasal Mediators

Role: collaborator

NCT01056783Phase 2Completed

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

Role: lead

NCT01448902Phase 2Completed

A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

Role: lead

NCT00890877Phase 2Completed

OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma

Role: lead

NCT01056575Phase 1Completed

Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4

Role: lead

NCT01057927Phase 2Completed

Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Role: lead

NCT01056692Phase 2Completed

OC000459 Bronchial Allergen Challenge

Role: lead

NCT00697281Phase 2Completed

OC000459 Dose Finding Study in Hay Fever Sufferers.

Role: lead

All 8 trials loaded